MEP11809A - Jedinjenje indola - Google Patents

Jedinjenje indola

Info

Publication number
MEP11809A
MEP11809A MEP-118/09A MEP11809A MEP11809A ME P11809 A MEP11809 A ME P11809A ME P11809 A MEP11809 A ME P11809A ME P11809 A MEP11809 A ME P11809A
Authority
ME
Montenegro
Prior art keywords
indole compound
present
glucokinase activator
prodrug
prophylaxis
Prior art date
Application number
MEP-118/09A
Other languages
English (en)
Inventor
Tsuneo Yasuma
Osamu Ujikawa
Masahiro Itoh
Kazuko Aoki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39010108&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP11809(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of ME00681B publication Critical patent/ME00681B/me
Publication of MEP11809A publication Critical patent/MEP11809A/bs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Svrha ovog pronalaska je da obezbijedi akti vator glukokinaze koristan kao farmaceutsko sredstvo kao što je sredstvo za profi laksu ili tretman dijabeti sa, gojaznosti i sl. Ovaj pronalazak obezbjeđuje akti vator glukokinaze koji sadrži jedinjenje predstavljeno formulom (I): gdje R1 je atom vodonika ili atom halogene; R2 je grupa predstavljena sa Gdje je svaki simbol defi nisan u specifi kacij, ili njegovu so ili njegov prolek.
MEP-118/09A 2006-10-19 2007-10-18 Jedinjenje indola MEP11809A (bs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006285551 2006-10-19
PCT/JP2007/070772 WO2008050821A1 (en) 2006-10-19 2007-10-18 Indole compound

Publications (2)

Publication Number Publication Date
ME00681B ME00681B (me) 2011-12-20
MEP11809A true MEP11809A (bs) 2011-12-20

Family

ID=39010108

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-118/09A MEP11809A (bs) 2006-10-19 2007-10-18 Jedinjenje indola

Country Status (26)

Country Link
US (4) US8410087B2 (bs)
EP (2) EP2508524A3 (bs)
JP (1) JP5260507B2 (bs)
KR (1) KR101444486B1 (bs)
CN (1) CN101573357B (bs)
AU (1) AU2007310064B2 (bs)
BR (1) BRPI0717722A2 (bs)
CA (1) CA2666973C (bs)
CL (1) CL2008001017A1 (bs)
CR (1) CR10748A (bs)
EC (1) ECSP099330A (bs)
GE (1) GEP20115241B (bs)
IL (1) IL198154A (bs)
MA (1) MA30890B1 (bs)
ME (1) MEP11809A (bs)
MX (1) MX2009003972A (bs)
MY (1) MY158052A (bs)
NO (1) NO20091948L (bs)
NZ (1) NZ576570A (bs)
PE (1) PE20090884A1 (bs)
RU (1) RU2454415C9 (bs)
TN (1) TN2009000129A1 (bs)
TW (1) TWI460176B (bs)
UA (1) UA97257C2 (bs)
WO (1) WO2008050821A1 (bs)
ZA (1) ZA200902585B (bs)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY162157A (en) * 2007-04-16 2017-05-31 Abbott Lab Substituted indole mcl-1 inhibitors
JPWO2008136428A1 (ja) 2007-04-27 2010-07-29 武田薬品工業株式会社 含窒素５員複素環化合物
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DK2178870T3 (en) * 2007-08-17 2018-10-22 Lg Chemical Ltd INDOLE AND INDAZOLIC COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSE
KR101133772B1 (ko) * 2007-12-20 2012-04-24 주식회사 엘지생명과학 글루코키나아제 활성화제 및 이를 활성성분으로 함유하는 약제학적 조성물
US20100291533A1 (en) * 2008-01-04 2010-11-18 Soon Ha Kim Indole and indazole derivatives having a cell-, tissue- and organ-preserving effect
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
RS53378B (sr) 2008-04-10 2014-10-31 Takeda Pharmaceutical Company Limited Jedinjenja sa kondenzovanim prstenom i njihova upotreba
JPWO2009128481A1 (ja) * 2008-04-16 2011-08-04 武田薬品工業株式会社 含窒素５員複素環化合物
AR072297A1 (es) * 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
JP5597200B2 (ja) * 2008-08-18 2014-10-01 プロメガ コーポレイション ルミネッセンスを生じる化合物およびチトクロムｐ４５０３ａ酵素を検出するための方法
UY32126A (es) 2008-09-25 2010-04-30 Takeda Pharmaceutical Composición farmacéutica sólida
WO2010050445A1 (ja) 2008-10-27 2010-05-06 武田薬品工業株式会社 二環性化合物
US8557805B2 (en) 2008-12-29 2013-10-15 Takeda Pharmaceutical Company Limited Fused ring compound and use thereof
US20120022078A1 (en) * 2009-04-09 2012-01-26 Msd K.K. Aryl indole derivatives
WO2010143733A1 (en) 2009-06-09 2010-12-16 Takeda Pharmaceutical Company Limited Novel fused cyclic compound and use thereof
EA201270204A1 (ru) 2009-07-28 2012-08-30 Такеда Фармасьютикал Компани Лимитед Таблетка
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011136385A1 (en) 2010-04-27 2011-11-03 Takeda Pharmaceutical Company Limited Bicyclic compound derivatives and their use as acc inhibitors.
US9018374B2 (en) 2010-06-16 2015-04-28 Takeda Pharmaceutical Company Limited Crystal of amide compound
WO2011159781A2 (en) * 2010-06-17 2011-12-22 Senomyx, Inc. Bitter taste modulators
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EP2617726A4 (en) 2010-09-17 2014-05-14 Takeda Pharmaceutical DIABETES THERAPEUTIC
ES2536319T3 (es) 2010-11-30 2015-05-22 Takeda Pharmaceutical Company Limited Compuestos bicíclicos como inhibidores de acetil-CoA carboxilasa (ACC)
JP5945545B2 (ja) 2011-02-17 2016-07-05 武田薬品工業株式会社 光学活性なジヒドロベンゾフラン誘導体の製造法
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2781521A4 (en) * 2011-10-19 2015-03-04 Kowa Co NEW SPIROINDOLIN COMPOUND AND MEDICAL AGENT THEREFOR
US9133129B2 (en) 2011-10-24 2015-09-15 Takeda Pharmaceutical Company Limited Bicyclic compound
US9365540B2 (en) 2012-01-12 2016-06-14 Takeda Pharmaceutical Company Limited Benzimidazole derivatives as MCH receptor antagonists
WO2013122028A1 (ja) 2012-02-13 2013-08-22 武田薬品工業株式会社 芳香環化合物
JP6121339B2 (ja) 2012-02-13 2017-04-26 武田薬品工業株式会社 芳香環化合物
CA2864068A1 (en) 2012-02-15 2013-08-22 Takeda Pharmaceutical Company Limited Tablet comprising 1-(4-methoxybutyl)-n-(2-methylpropyl)-n-[(3s,5r)-5-(morpholin-4-ylcarbonyl)piperidin-3-yl]-1h-benzimidazole-2-carboxamide or a salt thereof
US9238639B2 (en) 2012-02-24 2016-01-19 Takeda Pharmaceutical Company Limited Aromatic ring compound
CA2868713A1 (en) 2012-03-29 2013-10-03 Takeda Pharmaceutical Company Limited Aromatic ring compound
EP2836482B1 (en) 2012-04-10 2019-12-25 The Regents of The University of California Compositions and methods for treating cancer
EP2848621A4 (en) 2012-05-10 2016-06-01 Takeda Pharmaceutical AROMATIC RING CONNECTION
US9505772B2 (en) 2012-05-10 2016-11-29 Takeda Pharmaceutical Company Limited Aromatic ring compound
AR092843A1 (es) 2012-06-05 2015-05-06 Takeda Pharmaceuticals Co Preparacion solida
JP2015127299A (ja) 2012-07-19 2015-07-09 武田薬品工業株式会社 固形製剤
WO2014085486A2 (en) 2012-11-30 2014-06-05 Waters Technologies Corporation Methods and apparatus for the analysis of vitamin d metabolites
JP6247697B2 (ja) 2013-03-14 2017-12-13 武田薬品工業株式会社 スピロアゼチジンイソキサゾール誘導体及びそのｓｓｔｒ５アンタゴニストとしての使用
US10005720B2 (en) 2013-04-05 2018-06-26 North Carolina Central University Compounds useful for the treatment of metabolic disorders and synthesis of the same
US9199963B2 (en) 2013-07-09 2015-12-01 Takeda Pharmaceutical Company Limited Heterocyclic compound
PL3031799T3 (pl) 2013-08-09 2018-09-28 Takeda Pharmaceutical Company Limited Związek aromatyczny
EP3037412B1 (en) * 2013-08-22 2020-09-30 LG Chem, Ltd. Indole amide compound as inhibitor of necrosis
JO3442B1 (ar) 2013-10-07 2019-10-20 Takeda Pharmaceuticals Co مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
CN104098498A (zh) * 2014-07-30 2014-10-15 天津市斯芬克司药物研发有限公司 一种吲唑类化合物及其制备方法
AR111307A1 (es) 2017-03-30 2019-06-26 Takeda Pharmaceuticals Co Derivados de 1’,2’-dihidroespiro[ciclohexan-1,3’-indol] o 1’,2’-dihidroespiro[ciclohexan-1,3’-pirrolo[3,2-b]piridina] como inhibidores de hexakisfosfato quinasa
JOP20190211A1 (ar) 2017-03-31 2019-09-15 Takeda Pharmaceuticals Co ببتيد منشط لمستقبل gip
WO2018181847A1 (ja) 2017-03-31 2018-10-04 武田薬品工業株式会社 芳香環化合物
AR111199A1 (es) 2017-03-31 2019-06-12 Takeda Pharmaceuticals Co Compuesto aromático agonista de gpr40
MX2020009950A (es) 2018-03-23 2021-04-28 Carmot Therapeutics Inc Moduladores de receptores acoplados a proteina g.
TW202024028A (zh) 2018-08-27 2020-07-01 日商思可海雅藥品股份有限公司 苯甲酸酯化合物
US12122815B2 (en) 2018-09-24 2024-10-22 Takeda Pharmaceutical Company Limited GIP receptor agonist peptide compounds and uses thereof
EP3856339A1 (en) 2018-09-24 2021-08-04 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
CN109250963B (zh) * 2018-09-29 2021-07-16 福建省昊立建设工程有限公司 一种复合增韧混凝土及其制备方法
HRP20241159T1 (hr) 2020-02-07 2024-12-06 Gasherbrum Bio, Inc. Heterociklički agonisti za glp-1
CN115916812A (zh) 2020-03-25 2023-04-04 武田药品工业株式会社 Gip受体激动剂肽化合物及其用途
CN115335395A (zh) 2020-03-25 2022-11-11 武田药品工业株式会社 Gip受体激动剂肽化合物的qd给药及其用途
CN113563306B (zh) * 2020-04-28 2022-07-01 新发药业有限公司 一种2-(4-苯氧基苯基)-6-(哌啶-4-)基烟酰胺的制备方法
TW202206429A (zh) 2020-04-29 2022-02-16 美商迦舒布魯姆生物有限公司 雜環ｇｌｐ—１促效劑
US12281149B2 (en) 2021-05-13 2025-04-22 Carmot Therapeutics, Inc. Modulators of G-protein coupled receptors
JP2025509281A (ja) 2022-03-09 2025-04-11 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式ｇｌｐ－１アゴニスト
US20250206757A1 (en) 2022-03-21 2025-06-26 Gasherbrum Bio, Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
US20250250269A1 (en) 2022-04-14 2025-08-07 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
TW202435857A (zh) 2022-12-15 2024-09-16 美商迦舒布魯姆生物有限公司 具有glp-1促效劑活性之化合物之鹽及固體形式
JP2026501286A (ja) 2022-12-22 2026-01-14 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式ｇｌｐ－１アゴニスト
WO2024131869A1 (en) 2022-12-22 2024-06-27 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN120957993A (zh) 2023-02-16 2025-11-14 加舒布鲁姆生物公司 杂环glp-1激动剂
EP4735456A1 (en) 2023-06-30 2026-05-06 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
TW202519220A (zh) 2023-07-13 2025-05-16 美商雅空嘉閣生物公司 化合物、組合物及方法
AR133240A1 (es) 2023-07-13 2025-09-10 Aconcagua Bio Inc Compuestos, composiciones y métodos
WO2025045208A1 (en) 2023-08-31 2025-03-06 Gasherbrum Bio, Inc. Heteroaryl-heterocycloalkyl-based glp-1 agonists
US20250188081A1 (en) * 2023-12-08 2025-06-12 Shaman Pharma, LLC Method for Production of Spiro-Oxindole and Indoxyl Derivatives of Mitragynine
WO2025137307A1 (en) 2023-12-20 2025-06-26 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2025154021A1 (en) 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof
WO2025154020A1 (en) 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof
WO2025171340A1 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. The treatment of calcitonin- and/or amylin-receptor associated conditions
WO2026041075A1 (en) 2024-08-21 2026-02-26 Gasherbrum Bio, Inc. Gpl-1 agonists
WO2026051998A1 (en) 2024-09-04 2026-03-12 Aconcagua Bio, Inc. Compounds, compositions, and methods

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2656610B1 (fr) 1989-12-29 1992-05-07 Sanofi Sa Derives d'amino-2 phenyl-4 thiazole, leur procede de preparation et leur application therapeutique.
JP3545461B2 (ja) * 1993-09-10 2004-07-21 エーザイ株式会社 二環式ヘテロ環含有スルホンアミド誘導体
WO1995007276A1 (en) 1993-09-10 1995-03-16 Eisai Co., Ltd. Bicyclic heterocyclic sulfonamide and sulfonic ester derivatives
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
SK12752000A3 (sk) * 1998-02-25 2001-03-12 Genetics Institute, Inc. Inhibítory fosfolipázových enzýmov, farmaceutický prostriedok s ich obsahom a ich použitie
JP4007743B2 (ja) 1999-02-26 2007-11-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害剤
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
GB0003636D0 (en) * 2000-02-16 2000-04-05 Smithkline Beecham Plc Novel compounds
EP1285651B1 (en) 2000-04-28 2010-09-01 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonists
US7229986B2 (en) 2000-05-16 2007-06-12 Takeda Pharmaceutical Company Ltd. Melanin-concentrating hormone antagonist
PL375149A1 (en) * 2002-10-03 2005-11-28 F.Hoffmann-La Roche Ag Indole-3-carboxamides as glucokinase (gk) activators
EP1532980A1 (en) * 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
US7498445B2 (en) * 2004-05-05 2009-03-03 Renopharm Ltd. Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof
EP1632491A1 (en) * 2004-08-30 2006-03-08 Laboratorios Del Dr. Esteve, S.A. Substituted indole compounds and their use as 5-HT6 receptor modulators
US8957070B2 (en) 2005-04-20 2015-02-17 Takeda Pharmaceutical Company Limited Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity
WO2007037543A1 (ja) 2005-09-29 2007-04-05 Banyu Pharmaceutical Co., Ltd. ビアリールアミド誘導体
WO2007037534A1 (ja) 2005-09-30 2007-04-05 Banyu Pharmaceutical Co., Ltd. ２－へテロアリール置換インドール誘導体
NZ583267A (en) 2007-08-14 2012-03-30 Bayer Schering Pharma Ag Fused bicyclic pyrimidines
WO2009021990A1 (en) 2007-08-14 2009-02-19 Bayer Schering Pharma Aktiengesellschaft Fused imidazoles for cancer treatment
CA2697974C (en) 2007-10-18 2015-06-30 Janssen Pharmaceutica Nv Trisubstituted 1,2,4-triazoles
JO2784B1 (en) 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative

Also Published As

Publication number Publication date
US7718798B2 (en) 2010-05-18
US20080096877A1 (en) 2008-04-24
TWI460176B (zh) 2014-11-11
TN2009000129A1 (en) 2010-10-18
CA2666973A1 (en) 2008-05-02
US20090286975A1 (en) 2009-11-19
PE20090884A1 (es) 2009-08-05
CN101573357B (zh) 2013-01-23
RU2454415C9 (ru) 2013-02-27
ME00681B (me) 2011-12-20
GEP20115241B (en) 2011-06-10
TW200825071A (en) 2008-06-16
US20100137610A1 (en) 2010-06-03
MY158052A (en) 2016-08-30
CN101573357A (zh) 2009-11-04
EP2508524A3 (en) 2012-10-24
ZA200902585B (en) 2010-09-29
AU2007310064A2 (en) 2009-06-04
JP5260507B2 (ja) 2013-08-14
JP2010506825A (ja) 2010-03-04
NZ576570A (en) 2010-11-26
WO2008050821A1 (en) 2008-05-02
KR20090068292A (ko) 2009-06-25
US20100144702A1 (en) 2010-06-10
CR10748A (es) 2009-05-20
US7652133B2 (en) 2010-01-26
ECSP099330A (es) 2009-06-30
IL198154A0 (en) 2009-12-24
EP2074119A1 (en) 2009-07-01
US7777047B2 (en) 2010-08-17
KR101444486B1 (ko) 2014-09-24
US8410087B2 (en) 2013-04-02
MX2009003972A (es) 2009-04-27
EP2508524A2 (en) 2012-10-10
CA2666973C (en) 2015-03-31
BRPI0717722A2 (pt) 2013-10-29
CL2008001017A1 (es) 2009-04-24
AU2007310064A1 (en) 2008-05-02
IL198154A (en) 2014-08-31
RU2009118602A (ru) 2010-11-27
NO20091948L (no) 2009-07-13
MA30890B1 (fr) 2009-11-02
UA97257C2 (en) 2012-01-25
RU2454415C2 (ru) 2012-06-27
AU2007310064B2 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
MEP11809A (bs) Jedinjenje indola
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
PH12014501033A1 (en) Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
TW201000473A (en) Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
MX2010011217A (es) Inhibidores de piridilo para señalizacion hedgehog.
BRPI0913457B8 (pt) Composto e composição farmacêutica
TW200833675A (en) Nicotinamide derivatives
MX2010009736A (es) Compuesto heterociclico.
MY153915A (en) Organic compounds
MX2010005649A (es) Compuestos novedosos como ligandos del receptor canabinoide y sus usos.
MX2009008779A (es) Composicion farmacéutica que comprende derivado de pirazina y método para usar el derivado de pirazina en combinación.
SMAP201100019A (it) Composti organici.
MX2009000884A (es) Derivados de piridizinona.
PH12013500745A1 (en) Azaadamantane derivatives and methods of use
DK2134691T3 (da) Quinolinonderivativer som parp- og tank-inhibitorer
UA105185C2 (uk) Піроли
IN2012DN00869A (bs)
UA94944C2 (ru) 2,4-диаминопиримидины как ингибиторы киназ, которые принимают участие в регуляции клеточного цикла
NO20081217L (no) Nye benzotiazolonderivater
MX2010008460A (es) Derivado de tiazol y su uso como inhibidor de proteina-1 de adhesion vascular.
EA200601391A1 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
JO2673B1 (en) New diosmetin compounds, a process for their preparation and pharmaceutical compositions containing them
CY1115247T1 (el) Ενωσεις συμπυκνωμενων δακτυλιων και χρηση αυτων
ATE517873T1 (de) 6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten
MY158069A (en) Tricyclic compound and pharmaceutical use thereof